On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer

Authors

  • Cornelius J. McGinn M.D.,

    Corresponding author
    1. Department of Radiation Oncology, University of Michigan Health Systems, Ann Arbor, Michigan
    • Department of Radiation Oncology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0010
    Search for more papers by this author
    • Fax: (734) 763-7370

  • Theodore S. Lawrence M.D., Ph.D.,

    1. Department of Radiation Oncology, University of Michigan Health Systems, Ann Arbor, Michigan
    Search for more papers by this author
  • Mark M. Zalupski M.D.

    1. Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Health Systems, Ann Arbor, Michigan
    Search for more papers by this author

Abstract

The use of chemotherapy with concurrent radiation therapy remains a standard treatment option for patients with unresectable or resected adenocarcinoma of the pancreas. This treatment strategy is based in large part on data from serial Gastrointestinal Tumor Study Group trials that have included 5-fluorouracil. Unfortunately, the majority of patients continue to succumb to the disease process. Recently, there has been a resurgence in clinical trials utilizing gemcitabine as a single agent, in combination chemotherapy regimens, and with concurrent radiation therapy. Use with concurrent radiation therapy is based in part on laboratory studies investigating mechanisms of radiosensitization and strategies that might increase the therapeutic index. In the current review, the authors summarize the preclinical data that support the use of gemcitabine as a radiosensitizing agent and the clinical trials that have been conducted to date. Issues regarding the use of gemcitabine in concurrent radiotherapy regimens need to be viewed in the context of both local and distant disease control, given the radiosensitizing and systemic activity of this agent. Cancer 2002;95:933–40. © 2002 American Cancer Society.

DOI 10.1002/cncr.10754

Ancillary